The Oncology 2 – Translational Clinical Integrated Review Group (OTC IRG) will consider applications involving translational and clinical investigations that encompass cancer prevention, diagnosis and treatment. Specifically, the OTC IRG reviews research grant applications related to mechanism of action of cancer therapeutic agents in both in vitro and in vivo model systems; development and evaluation of experimental therapies of neoplastic diseases; translation of basic research to clinical practice; development or optimization of treatment modalities; radiation biology and therapy; chemoprevention; and development of biomarkers/signatures for tumor detection and diagnosis.
Research project grant (R01, R21, R15, R03, etc), Small Business and Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications are reviewed in the OTC IRG.
|